2- (3- (1- carboxy- 5- (4- iodobenzylamino)pentyl)ureido)pentanedioic acid

Also Known As:

(S)-2-(3-((S)-1-carboxy-(4-iodobenzamido)pentyl)ureido) pentane dioic acid; DCIBzl; MIP 1072; MIP-1072; MIP1072

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Amino Acids: 30675
  - Acidic Amino Acids: 44
    - Glutamates: 45
      - 2-(3-(1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)pentanedioic acid: 3
  - Dicarboxylic Amino Acids: 20
    - Glutamates: 45
      - 2-(3-(1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)pentanedioic acid: 3
Organic Chemicals: 133
- Amides: 2428
  - Urea: 15015
    - 2-(3-(1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)pentanedioic acid: 3

Experts

1.	Pomper, Martin G: 2 articles (01/2020 - 09/2009)
2.	Banerjee, Sangeeta R: 1 article (01/2020)
3.	Brayton, Cory F: 1 article (01/2020)
4.	Brummet, Mary: 1 article (01/2020)
5.	Chen, Ying: 1 article (01/2020)
6.	Hobbs, Robert F: 1 article (01/2020)
7.	Josefsson, Anders: 1 article (01/2020)
8.	Kiess, Ana P: 1 article (01/2020)
9.	Mease, Ronnie C: 1 article (01/2020)
10.	Minn, Il: 1 article (01/2020)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 01/01/2020 - "Here, we investigated the therapeutic efficacy, long-term toxicity, and biodistribution of 125I-DCIBzL in a micrometastatic model of prostate cancer (PC). " 01/01/2018 - "A competitive binding assay was performed using the PSMA-positive prostate cancer cell line 22Rv1 and [125I]MIP-1072 (PSMA-specific binding agent) as a tracer. " 09/01/2009 - "MIP-1072 and MIP-1095 potently inhibited the glutamate carboxypeptidase activity of PSMA (K(i) = 4.6 +/- 1.6 nmol/L and 0.24 +/- 0.14 nmol/L, respectively) and, when radiolabeled with (123)I, exhibited high affinity for PSMA on human prostate cancer LNCaP cells (K(d) = 3.8 +/- 1.3 nmol/L and 0.81 +/- 0.39 nmol/L, respectively). " 09/01/2009 - "The association of [(123)I]MIP-1072 and [(123)I]MIP-1095 with PSMA was specific; there was no binding to human prostate cancer PC3 cells, which lack PSMA, and binding was abolished by coincubation with a structurally unrelated NAALADase inhibitor, 2-(phosphonomethyl)pentanedioic acid (PMPA). "
2.	Neoplasms (Cancer) 09/01/2009 - "The uptake of [(123)I]MIP-1072 and [(123)I]MIP-1095 in tumor-bearing mice was corroborated by single-photon emission computed tomography/computed tomography (SPECT/CT) imaging. " 09/01/2009 - "[(123)I]MIP-1095 exhibited greater tumor uptake but slower washout from blood and nontarget tissues compared with [(123)I]MIP-1072. " 01/01/2020 - "We previously demonstrated anti-tumor efficacy of a small-molecule Auger electron emitter targeting the prostate-specific membrane antigen (PSMA), 2-[3-[1-carboxy-5-(4-[125I]iodo-benzoylamino)-pentyl]-ureido]-pentanedioic acid), or 125I-DCIBzL, in a mouse xenograft model. "
3.	Neoplasm Metastasis (Metastasis) 01/01/2020 - "Gross metastases were detectable in control mice and those treated with 0.37-3.7 MBq 125I-DCIBzL at a median of 2 weeks post-treatment, versus 4 weeks for those treated with 18.5-111 MBq 125I-DCIBzL (P<0.0001 by log-rank test). "

Related Drugs and Biologics

1.	Antigens
2.	Acids
3.	Glutamate Carboxypeptidase II (N-Acetylaspartylglutamate Peptidase)
4.	2- (3- (1- carboxy- 5- (3- (4- iodobphenyl)ureido)pentyl)ureido)pentanedioic acid
5.	2-(phosphonomethyl)pentanedioic acid
6.	glutamate carboxypeptidase